{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:39:25Z","timestamp":1794746365202,"version":"4.9.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder that results in elevated concentrations of phenylalanine (Phe) in the blood. If left untreated, the accumulation of Phe can result in profound neurocognitive disability. The objective of this systematic literature review and meta-analysis was to estimate the global birth prevalence of PAH deficiency from newborn screening studies and to estimate regional differences, overall and for various clinically relevant Phe cutoff values used in confirmatory testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The protocol for this literature review was registered with PROSPERO (International prospective register of systematic reviews). Pubmed and Embase database searches were used to identify studies that reported the birth prevalence of PAH deficiency. Only studies including numeric birth prevalence reports of confirmed PAH deficiency were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From the 85 publications included in the review, 238 birth prevalence estimates were extracted. After excluding prevalence estimates that did not meet quality assessment criteria or because of temporal and regional overlap, estimates from 45 publications were included in the meta-analysis. The global birth prevalence of PAH deficiency, estimated by weighting regional birth prevalences relative to their share of the population of all regions included in the study, was 0.64 (95% confidence interval [CI] 0.53\u20130.75) per 10,000 births and ranged from 0.03 (95% CI 0.02\u20130.05) per 10,000 births in Southeast Asia to 1.18 (95% CI 0.64\u20131.87) per 10,000 births in the Middle East\/North Africa. Regionally weighted global birth prevalences per 10,000 births by confirmatory test Phe cutoff values were 0.96 (95% CI 0.50\u20131.42) for the Phe cutoff value of 360\u2009\u00b1\u2009100\u00a0\u00b5mol\/L; 0.50 (95% CI 0.37\u20130.64) for the Phe cutoff value of 600\u2009\u00b1\u2009100\u00a0\u00b5mol\/L; and 0.30 (95% CI 0.20\u20130.40) for the Phe cutoff value of 1200\u2009\u00b1\u2009200\u00a0\u00b5mol\/L.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Substantial regional variation in the birth prevalence of PAH deficiency was observed in this systematic literature review and meta-analysis of published evidence from newborn screening. The precision of the prevalence estimates is limited by relatively small sample sizes, despite widespread and longstanding newborn screening in much of the world.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-021-01874-6","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T09:03:16Z","timestamp":1622710996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Pamela K.","family":"Foreman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Shediac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Calingaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abenah","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Pladevall-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-3958","authenticated-orcid":false,"given":"Sarah","family":"Landis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"9","key":"1874_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"FJ van Spronsen","year":"2017","unstructured":"van Spronsen FJ, van Wegberg AM, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1874_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1874_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188\u2013200.","journal-title":"Genet Med"},{"issue":"6","key":"1874_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/humu.22980","volume":"37","author":"N Blau","year":"2016","unstructured":"Blau N. Genetics of phenylketonuria: then and now. Hum Mutat. 2016;37(6):508\u201315.","journal-title":"Hum Mutat"},{"key":"1874_CR5","unstructured":"PAHvdb: Phenylalanine Hydroxylase Gene Locus-Specific Database. 2020. http:\/\/www.biopku.org\/home\/pah.asp. Accessed 4 Sept 2020."},{"issue":"1","key":"1874_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13023-020-01379-8","volume":"15","author":"T Opladen","year":"2020","unstructured":"Opladen T, L\u00f3pez-Laso E, Cort\u00e8s-Saladelafont E, Pearson TS, Sivri HS, Yildiz Y, et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH(4)) deficiencies. Orphanet J Rare Dis. 2020;15(1):126.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1874_CR7","first-page":"31","volume":"29","author":"RA Williams","year":"2008","unstructured":"Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev. 2008;29(1):31\u201341.","journal-title":"Clin Biochem Rev"},{"issue":"2","key":"1874_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ajhg.2017.01.002","volume":"100","author":"Y Anikster","year":"2017","unstructured":"Anikster Y, Haack TB, Vilboux T, Pode-Shakked B, Thony B, Shen N, et al. Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet. 2017;100(2):257\u201366.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1874_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","volume":"15","author":"A MacDonald","year":"2020","unstructured":"MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, B\u00e9langer-Quintana A, Burlina A, et al. PKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15(1):171.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1874_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13023-020-01486-6","volume":"15","author":"A MacDonald","year":"2020","unstructured":"MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, B\u00e9langer-Quintana A, Burlina A, et al. Correction to: PKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15(1):230.","journal-title":"Orphanet J Rare Dis"},{"key":"1874_CR11","unstructured":"European Medicines Agency. Palynziq\u2014Summary of product characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/palynziq-epar-product-information_en.pdf. Accessed 4 Sept 2020."},{"key":"1874_CR12","unstructured":"FDA. Palynziq\u2014US package insert. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761079s000lbl.pdf."},{"key":"1874_CR13","unstructured":"European Medicines Agency. Kuvan\u2014Summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kuvan-epar-product-information_en.pdf. Accessed 4 Sept 2020."},{"key":"1874_CR14","unstructured":"FDA. Kuvan - US package insert. 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022181lbl.pdf. Accessed 4 Sep 2020."},{"issue":"3","key":"1874_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.semperi.2015.03.002","volume":"39","author":"BL Therrell","year":"2015","unstructured":"Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171\u201387.","journal-title":"Semin Perinatol"},{"issue":"10","key":"1874_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-015-0283-0","volume":"30","author":"M Zerjav Tansek","year":"2015","unstructured":"Zerjav Tansek M, Groselj U, Angelkova N, Anton D, Baric I, Djordjevic M, et al. Phenylketonuria screening and management in southeastern Europe\u2014survey results from 11 countries. Orphanet J Rare Dis. 2015;30(10):68.","journal-title":"Orphanet J Rare Dis"},{"key":"1874_CR17","doi-asserted-by":"crossref","unstructured":"Borrajo GJC. Newborn screening for phenylketonuria: Latin American consensus guidelines. J Inborn Errors Metab Screen. 2016 2016\/01\/01;4:2326409816682764.","DOI":"10.1177\/2326409816682764"},{"key":"1874_CR18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1542\/peds.32.3.338","volume":"32","author":"R Guthrie","year":"1963","unstructured":"Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338\u201343.","journal-title":"Pediatrics"},{"key":"1874_CR19","doi-asserted-by":"crossref","unstructured":"Chace DH, Hannon WH. Technological journey from colorimetric to tandem mass spectrometric measurements in the diagnostic investigation for phenylketonuria. J Inborn Errors Metab Screen. 2016 2016\/01\/01;4:2326409816671733.","DOI":"10.1177\/2326409816671733"},{"issue":"6","key":"1874_CR20","first-page":"429","volume":"105","author":"CM Blumenfeld","year":"1966","unstructured":"Blumenfeld CM, Wallace MJ, Anderson R. Phenylketonuria-the guthrie screening test-a method of quantitation, observations on reliability and suggestions for improvement. Calif Med. 1966;105(6):429\u201334.","journal-title":"Calif Med"},{"issue":"339","key":"1874_CR21","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"21","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;21(339):b2535.","journal-title":"BMJ"},{"issue":"3","key":"1874_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1590\/S1020-49892001000900002","volume":"10","author":"LC Silva","year":"2001","unstructured":"Silva LC, Ordunez P, Paz Rodriguez M, Robles S. A tool for assessing the usefulness of prevalence studies done for surveillance purposes: the example of hypertension. Rev Panam Salud Publica. 2001;10(3):152\u201360.","journal-title":"Rev Panam Salud Publica"},{"issue":"3","key":"1874_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1034\/j.1399-0004.2002.620308.x","volume":"62","author":"LN Al-Jader","year":"2002","unstructured":"Al-Jader LN, Newcombe RG, Hayes S, Murray A, Layzell J, Harper PS. Developing a quality scoring system for epidemiological surveys of genetic disorders. Clin Genet. 2002;62(3):230\u20134.","journal-title":"Clin Genet"},{"key":"1874_CR24","unstructured":"United Nations. World population prospects 2019. File POP\/1\u20131: total population (both sexes combined) by region, subregion and country, annually for 1950\u20132100 (thousands). 2019. https:\/\/population.un.org\/wpp\/. Accessed 28 May 28 2020."},{"issue":"11","key":"1874_CR25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Commun Health. 2013;67(11):974\u20138.","journal-title":"J Epidemiol Commun Health."},{"key":"1874_CR26","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M. Cochrane handbook for systematic reviews of interventions, version 6.0. 2019. https:\/\/training.cochrane.org\/handbook. Accessed 5 March 2020.","DOI":"10.1002\/9781119536604"},{"issue":"7414","key":"1874_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"1874_CR28","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2105\/AJPH.54.12.2075","volume":"54","author":"RA Maccready","year":"1964","unstructured":"Maccready RA, Hussey MG. Newborn phenylketonuria detection program in Massachusetts. Am J Public Health Nations Health. 1964;54:2075\u201381.","journal-title":"Am J Public Health Nations Health"},{"key":"1874_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cca.2019.03.1622","volume":"494","author":"Y Lin","year":"2019","unstructured":"Lin Y, Zheng Q, Zheng T, Zheng Z, Lin W, Fu Q. Expanded newborn screening for inherited metabolic disorders and genetic characteristics in a southern Chinese population. Clin Chim Acta. 2019;494:106\u201311.","journal-title":"Clin Chim Acta"},{"issue":"228","key":"1874_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/adc.43.228.145","volume":"43","author":"NA Carson","year":"1968","unstructured":"Carson NA, Carre IJ, Neill DW. Results of routine screening for phenylketonuria in early infancy, Northern Ireland (1960\u20131967). Arch Dis Child. 1968;43(228):145\u20136.","journal-title":"Arch Dis Child"},{"issue":"4","key":"1874_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0925-6164(94)00022-Z","volume":"3","author":"JJ Arnopp","year":"1995","unstructured":"Arnopp JJ, Lorey FW, Currier RJ, Eastman JW, Velazquez KB, Morales DR, et al. Results of screening for phenylketonuria using a lower cutoff value in early collected specimens. Screening. 1995;3(4):193\u20139.","journal-title":"Screening"},{"issue":"8","key":"1874_CR32","first-page":"1107","volume":"61","author":"PH Martin","year":"1968","unstructured":"Martin PH. Six years of newborn PKU screening. J Indiana State Med Assoc. 1968;61(8):1107\u20138.","journal-title":"J Indiana State Med Assoc"},{"issue":"3","key":"1874_CR33","first-page":"143","volume":"17","author":"LL Yang","year":"2012","unstructured":"Yang LL, Mao HQ, Zhang WF, Zhao ZY, Yang RL, Zhou XL, et al. Pitfalls in the management of phenylketonuria in China. Hong Kong J Paediatr. 2012;17(3):143\u20137.","journal-title":"Hong Kong J Paediatr"},{"issue":"9","key":"1874_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1440-1754.2006.00909.x","volume":"42","author":"A Boneh","year":"2006","unstructured":"Boneh A, Francis DE, Humphrey M, Upton HJ, Peters HL. Three-year audit of the hyperphenylalaninaemia\/phenylketonuria spectrum in Victoria. J Paediatr Child Health. 2006;42(9):496\u20138.","journal-title":"J Paediatr Child Health"},{"issue":"13","key":"1874_CR35","first-page":"691","volume":"68","author":"KS Read","year":"1969","unstructured":"Read KS, Allen RJ, Haddy TB. Phenylketonuria in newborns. Mich Med. 1969;68(13):691\u20137.","journal-title":"Mich Med"},{"issue":"2","key":"1874_CR36","first-page":"30","volume":"61","author":"EN Ervin","year":"1970","unstructured":"Ervin EN. Hyperphenylalanemia. Incidence in Maine since 1964. J Maine Med Assoc. 1970;61(2):30\u20132.","journal-title":"J Maine Med Assoc"},{"issue":"3","key":"1874_CR37","first-page":"206","volume":"73","author":"DG Somers","year":"1982","unstructured":"Somers DG, Favreau L. Newborn screening for phenylketonuria: incidence and screening procedures in North America. Can J Public Health. 1982;73(3):206\u20137.","journal-title":"Can J Public Health"},{"issue":"1","key":"1874_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/jms.5.1.22","volume":"5","author":"K Ounap","year":"1998","unstructured":"Ounap K, Lillev\u00e4li H, Metspalu A, Lipping-Sitska M. Development of the phenylketonuria screening programme in Estonia. J Med Screen. 1998;5(1):22\u20133.","journal-title":"J Med Screen"},{"issue":"6","key":"1874_CR39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1651-2227.1971.tb07007.x","volume":"60","author":"JK Visakorpi","year":"1971","unstructured":"Visakorpi JK, Palo J, Renkonen OV. The incidence of PKU in Finland. Acta Paediatr Scand. 1971;60(6):666\u20138.","journal-title":"Acta Paediatr Scand"},{"issue":"Suppl 2","key":"1874_CR40","first-page":"28","volume":"30","author":"V Ratrisawadi","year":"1999","unstructured":"Ratrisawadi V, Horpaopan S, Chotigeat U, Sangtawesin V, Kanjanapattanakul W, Ningsanond V, et al. Neonatal screening program in Rajavithi Hospital, Thailand. Southeast Asian J Trop Med Public Health. 1999;30(Suppl 2):28\u201332.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"1","key":"1874_CR41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13023-016-0483-2","volume":"11","author":"M Kocova","year":"2016","unstructured":"Kocova M, Anastasovska V. Phenylketonuria screening in the Republic of Macedonia. Orphanet J Rare Dis. 2016;11(1):112.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1874_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s10545-006-0228-9","volume":"29","author":"DM Frazier","year":"2006","unstructured":"Frazier DM, Millington DS, McCandless SE, Koeberl DD, Weavil SD, Chaing SH, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997\u20132005. J Inherit Metab Dis. 2006;29(1):76\u201385.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"1874_CR43","first-page":"306","volume":"11","author":"SC Wainer","year":"1974","unstructured":"Wainer SC, Sideman L. Nine years of PKU screening in Pennsylvania. Health Lab Sci. 1974;11(4):306\u201311.","journal-title":"Health Lab Sci"},{"issue":"2","key":"1874_CR44","first-page":"137","volume":"35","author":"A Habib","year":"2010","unstructured":"Habib A, Fallahzadeh MH, Kazeroni HR, Ganjkarimi AH. Incidence of phenylketonuria in Southern Iran. Iran J Med Sci. 2010;35(2):137\u20139.","journal-title":"Iran J Med Sci"},{"issue":"9","key":"1874_CR45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/GIM.0b013e318217477f","volume":"13","author":"H Hamamy","year":"2011","unstructured":"Hamamy H, Antonarakis SE, Cavalli-Sforza LL, Temtamy S, Romeo G, Kate LP, et al. Consanguineous marriages, pearls and perils: Geneva International Consanguinity Workshop Report. Genet Med. 2011;13(9):841\u20137.","journal-title":"Genet Med"},{"issue":"2","key":"1874_CR46","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","volume":"107","author":"A Hillert","year":"2020","unstructured":"Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, et al. The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet. 2020;107(2):234\u201350.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"1874_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3345\/kjp.2019.00465","volume":"63","author":"HR Shoraka","year":"2020","unstructured":"Shoraka HR, Haghdoost AA, Baneshi MR, Bagherinezhad Z, Zolala F. Global prevalence of classic phenylketonuria based on Neonatal Screening Program data: systematic review and meta-analysis. Clin Exp Pediatr. 2020;63(2):34\u201343.","journal-title":"Clin Exp Pediatr"},{"issue":"9","key":"1874_CR48","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"15","key":"1874_CR49","first-page":"396","volume":"69","author":"O Thalhammer","year":"1976","unstructured":"Thalhammer O. Distribution and frequency of PKU and hyperphenylalaninemia in eastern and western Austria. Ir Med J. 1976;69(15):396\u20137.","journal-title":"Ir Med J"},{"key":"1874_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-6-44","volume":"6","author":"M Lindner","year":"2011","unstructured":"Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab KO, Tacke U, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases\u2013report of 10 years from South-West Germany. Orphanet J Rare Dis. 2011;6:44.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1874_CR51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/BF00439408","volume":"145","author":"D Mathias","year":"1986","unstructured":"Mathias D, Bickel H. Follow-up study of 16 years neonatal screening for inborn errors of metabolism in West Germany. Eur J Pediatr. 1986;145(4):310\u20132.","journal-title":"Eur J Pediatr"},{"issue":"6 Pt 1","key":"1874_CR52","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1542\/peds.111.6.1399","volume":"111","author":"A Schulze","year":"2003","unstructured":"Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111(6 Pt 1):1399\u2013406.","journal-title":"Pediatrics"},{"issue":"Suppl 3","key":"1874_CR53","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1007\/s10545-010-9181-8","volume":"33","author":"YL Loukas","year":"2010","unstructured":"Loukas YL, Soumelas GS, Dotsikas Y, Georgiou V, Molou E, Thodi G, et al. Expanded newborn screening in Greece: 30 months of experience. J Inherit Metab Dis. 2010;33(Suppl 3):S341\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"Pt 4","key":"1874_CR54","first-page":"271","volume":"32","author":"S Missiou-Tsagaraki","year":"1988","unstructured":"Missiou-Tsagaraki S, Soulpi K, Loumakou M. Phenylketonuria in Greece: 12 years\u2019 experience. J Ment Defic Res. 1988;32(Pt 4):271\u201387.","journal-title":"J Ment Defic Res"},{"issue":"2","key":"1874_CR55","first-page":"147","volume":"26","author":"K Mehes","year":"1985","unstructured":"Mehes K, Juhasz E, Ruszinko V. Chromatographic screening of 70,328 neonates for inborn errors of amino acid metabolism. Acta Paediatr Hung. 1985;26(2):147\u20139.","journal-title":"Acta Paediatr Hung"},{"issue":"4","key":"1874_CR56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF03349371","volume":"3","author":"I Antonozzi","year":"1980","unstructured":"Antonozzi I, Dominici R, Andreoli M, Monaco F. Neonatal screening in Italy for congenital hypothyroidism and metabolic disorders: hyperphenylalaninemia, maple syrup urine disease and homocystinuria. J Endocrinol Invest. 1980;3(4):357\u201363.","journal-title":"J Endocrinol Invest"},{"key":"1874_CR57","first-page":"479","volume":"28","author":"M Zaffanello","year":"2002","unstructured":"Zaffanello M, Zamboni G, Tat\u00f2 L. Neonatal screening program for inborn errors of metabolism: a retrospective study from 1978 to 1997 in Northeastern Italy. Ital J Pediatr. 2002;28:479\u201383.","journal-title":"Ital J Pediatr"},{"issue":"1","key":"1874_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0925-6164(93)90015-B","volume":"2","author":"B Cabalska","year":"1993","unstructured":"Cabalska B, Nowaczewska I, Duczynska N, Laskowska-Klita T. Twenty-five years experience with newborn screening for phenylketonuria (PKU) in Poland. Screening. 1993;2(1):29\u201332.","journal-title":"Screening"},{"issue":"Suppl 3","key":"1874_CR59","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1007\/s10545-010-9048-z","volume":"33","author":"L Vilarinho","year":"2010","unstructured":"Vilarinho L, Rocha H, Sousa C, Marcao A, Fonseca H, Bogas M, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis. 2010;33(Suppl 3):S133\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"1874_CR60","doi-asserted-by":"crossref","unstructured":"Dluholuck\u00fd S, Knapkov\u00e1 M. Newborn screening in Slovakia\u2014from 1985 till today\/Novorodenck\u00fd skr\u00edning na Slovensku\u2014od roku 1985 doposia\u013e. Acta Facul Pharm Univ Comen. 2013;60(Suppl VIII):32\u20136.","DOI":"10.2478\/afpuc-2013-0006"},{"issue":"2","key":"1874_CR61","first-page":"86","volume":"54","author":"A Smon","year":"2015","unstructured":"Smon A, Groselj U, Zerjav Tansek M, Bicek A, Oblak A, Zupancic M, et al. Newborn screening in Slovenia. Zdr Varst. 2015;54(2):86\u201390.","journal-title":"Zdr Varst"},{"issue":"3","key":"1874_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0925-6164(95)00119-0","volume":"4","author":"C Fern\u00e1ndez-Iglesias","year":"1995","unstructured":"Fern\u00e1ndez-Iglesias C, Fl\u00f3rez IG, Rodr\u00edguez-Gonz\u00e1lez MC, Gasc\u00f3n S. Neonatal screening for phenylketonuria and congenital hypothyroidism in Principado de Asturias (Spain) using two types of blood samples. Screening. 1995;4(3):131\u20138.","journal-title":"Screening"},{"issue":"1","key":"1874_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0925-6164(92)90027-3","volume":"1","author":"NS Gerasimova","year":"1992","unstructured":"Gerasimova NS, Samutin AA, Steklova IV, Tuuminen T. Phenylketonuria screening in Moscow using a microplate fluorometric method. Screening. 1992;1(1):27\u201335.","journal-title":"Screening"},{"issue":"10","key":"1874_CR64","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1136\/adc.56.10.759","volume":"56","author":"V Walker","year":"1981","unstructured":"Walker V, Clayton BE, Ersser RS, Francis DE, Lilly P, Seakins JW, et al. Hyperphenylalaninaemia of various types among three-quarters of a million neonates tested in a screening programme. Arch Dis Child. 1981;56(10):759\u201364.","journal-title":"Arch Dis Child"},{"issue":"Suppl 2","key":"1874_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/BF01799715","volume":"9","author":"D Mardesic","year":"1986","unstructured":"Mardesic D, Gjuric G, Jancikovic J. Screening for phenylketonuria in Yugoslavia (SR Crotia) 1979\u20131984. J Inherit Metab Dis. 1986;9(Suppl 2):234\u20136.","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"1874_CR66","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1590\/S0102-311X2012000900002","volume":"28","author":"J Botler","year":"2012","unstructured":"Botler J, Camacho LA, Cruz MM. Phenylketonuria, congenital hypothyroidism and haemoglobinopathies: public health issues for a Brazilian newborn screening program. Cad Saude Publica. 2012;28(9):1623\u201331.","journal-title":"Cad Saude Publica"},{"issue":"1","key":"1874_CR67","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1590\/0004-2730000002885","volume":"58","author":"AR Ramalho","year":"2014","unstructured":"Ramalho AR, Ramalho RJ, Oliveira CR, Magalhaes MM, Santos EG, Sarmento PM, et al. Evaluation of effectiveness and outcome of PKU screening and management in the state of Sergipe. Brazil Arq Bras Endocrinol Metabol. 2014;58(1):62\u20137.","journal-title":"Brazil Arq Bras Endocrinol Metabol"},{"issue":"Suppl 3","key":"1874_CR68","doi-asserted-by":"publisher","first-page":"S301","DOI":"10.1007\/s10545-010-9165-8","volume":"33","author":"V Cornejo","year":"2010","unstructured":"Cornejo V, Raimann E, Cabello JF, Valiente A, Becerra C, Opazo M, et al. Past, present and future of newborn screening in Chile. J Inherit Metab Dis. 2010;33(Suppl 3):S301\u20136.","journal-title":"J Inherit Metab Dis"},{"key":"1874_CR69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/ijpvm.IJPVM_24_17","volume":"8","author":"A Abbaskhanian","year":"2017","unstructured":"Abbaskhanian A, Zamanfar D, Afshar P, Asadpoor E, Rouhanizadeh H, Jafarnia A, et al. Incidence of neonatal hyperphenylalaninemia based on high-performance liquid chromatography confirmatory technique in Mazandaran province, northern Iran (2007\u20132015). Int J Prev Med. 2017;8:93.","journal-title":"Int J Prev Med"},{"issue":"2","key":"1874_CR70","first-page":"216","volume":"20","author":"H Karamifar","year":"2010","unstructured":"Karamifar H, Ordoei M, Karamizadeh Z, Amirhakimi G. Incidence of neonatal hyperphenylalaninemia in Fars province, south Iran. Iran J Pediatr. 2010;20(2):216\u201320.","journal-title":"Iran J Pediatr"},{"issue":"4","key":"1874_CR71","first-page":"4713","volume":"5","author":"N Motamedi","year":"2017","unstructured":"Motamedi N, Godarzi E, Pordanjani SR, Valizadeh R, Moradi Y, Sohrabivafa M, et al. Incidence of phenylketonuria in Lorestan province, west of Iran (2006\u20132016). Int J Pediatr. 2017;5(4):4713\u201321.","journal-title":"Int J Pediatr"},{"issue":"6","key":"1874_CR72","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/jpc.13469","volume":"53","author":"M Alfadhel","year":"2017","unstructured":"Alfadhel M, Al Othaim A, Al Saif S, Al Mutairi F, Alsayed M, Rahbeeni Z, et al. Expanded newborn screening program in Saudi Arabia: incidence of screened disorders. J Paediatr Child Health. 2017;53(6):585\u201391.","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"1874_CR73","first-page":"97","volume":"43","author":"I Ozalp","year":"2001","unstructured":"Ozalp I, Coskun T, Tokatli A, Kalkanoglu HS, Dursun A, Tokol S, et al. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr. 2001;43(2):97\u2013101.","journal-title":"Turk J Pediatr"},{"issue":"1","key":"1874_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.26719\/2014.20.1.17","volume":"20","author":"H Al Hosani","year":"2014","unstructured":"Al Hosani H, Salah M, Osman HM, Farag HM, El-Assiouty L, Saade D, et al. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. East Mediterr Health J. 2014;20(1):17\u201323.","journal-title":"East Mediterr Health J"},{"issue":"3","key":"1874_CR75","first-page":"246","volume":"93","author":"H Hansen","year":"1978","unstructured":"Hansen H, Shahidi A, Stein ZA. Screening for phenylketonuria in New York City Threshold values reconsidered. Public Health Rep. 1978;93(3):246\u201351.","journal-title":"Public Health Rep"},{"issue":"10","key":"1874_CR76","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2307\/4593161","volume":"82","author":"S Kelly","year":"1967","unstructured":"Kelly S, Palombi J. Phenylketonuria in New York State. Public Health Rep. 1967;82(10):921\u20134.","journal-title":"Public Health Rep"},{"issue":"11","key":"1874_CR77","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/clinchem\/47.11.1945","volume":"47","author":"TH Zytkovicz","year":"2001","unstructured":"Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001;47(11):1945\u201355.","journal-title":"Clin Chem"},{"issue":"Suppl 3","key":"1874_CR78","first-page":"94","volume":"34","author":"W Charoensiriwatana","year":"2003","unstructured":"Charoensiriwatana W, Janejai N, Boonwanich W, Krasao P, Chaisomchit S, Waiyasilp S. Neonatal screening program in Thailand. Southeast Asian J Trop Med Public Health. 2003;34(Suppl 3):94\u2013100.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"Suppl 3","key":"1874_CR79","first-page":"179","volume":"34","author":"S Pangkanon","year":"2003","unstructured":"Pangkanon S, Ratrisawadi V, Charoensiriwatana W, Techasena W, Boonpuan K, Srisomsap C, et al. Phenylketonuria detected by the neonatal screening program in Thailand. Southeast Asian J Trop Med Public Health. 2003;34(Suppl 3):179\u201381.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"3","key":"1874_CR80","first-page":"525","volume":"40","author":"S Pangkanon","year":"2009","unstructured":"Pangkanon S, Charoensiriwatana W, Janejai N, Boonwanich W, Chaisomchit S. Detection of phenylketonuria by the newborn screening program in Thailand. Southeast Asian J Trop Med Public Health. 2009;40(3):525\u20139.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"2","key":"1874_CR81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/2230-8210.81941","volume":"15","author":"Y Sutivijit","year":"2011","unstructured":"Sutivijit Y, Banpavichit A, Wiwanitkit V. Prevalence of neonatal hypothyroidism and phenylketonuria in Southern Thailand: a 10-year report. Indian J Endocrinol Metab. 2011;15(2):115\u20137.","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"1874_CR82","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/BF01802047","volume":"12","author":"RG Chen","year":"1989","unstructured":"Chen RG, Pan XS, Qian DL, Guo H. Twenty-one cases of phenylketonuria out of 358,767 newborns in Shanghai, China. J Inherit Metab Dis. 1989;12(4):485.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1874_CR83","first-page":"113","volume":"99","author":"SR Liu","year":"1986","unstructured":"Liu SR, Zuo QH. Newborn screening for phenylketonuria in eleven districts. Chin Med J (Engl). 1986;99(2):113\u20138.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"1874_CR84","first-page":"702","volume":"125","author":"R Maitusong","year":"2012","unstructured":"Maitusong R, Japaer R, Zhao ZY, Yang RL, Huang XL, Mao HQ. Newborn screening in Zhejiang. China Chin Med J (Engl). 2012;125(4):702\u20134.","journal-title":"China Chin Med J (Engl)"},{"key":"1874_CR85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/8904_2011_119","volume":"6","author":"XT Shi","year":"2012","unstructured":"Shi XT, Cai J, Wang YY, Tu WJ, Wang WP, Gong LM, et al. Newborn screening for inborn errors of metabolism in mainland china: 30 years of experience. JIMD Rep. 2012;6:79\u201383.","journal-title":"JIMD Rep"},{"issue":"12","key":"1874_CR86","doi-asserted-by":"publisher","first-page":"258","DOI":"10.21037\/atm.2019.05.16","volume":"7","author":"Y Su","year":"2019","unstructured":"Su Y, Wang H, Rejiafu N, Wu B, Jiang H, Chen H, et al. The molecular epidemiology of hyperphenylalaninemia in Uygur population: incidence from newborn screening and mutational spectra. Ann Transl Med. 2019;7(12):258.","journal-title":"Ann Transl Med"},{"issue":"4","key":"1874_CR87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1258\/jms.2011.011125","volume":"18","author":"WJ Tu","year":"2011","unstructured":"Tu WJ, Cai J, Shi XD. Newborn screening for inborn errors of metabolism in Beijing, China: 22 years of experience. J Med Screen. 2011;18(4):213\u20134.","journal-title":"J Med Screen"},{"key":"1874_CR88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2019.08.021","volume":"498","author":"X Wang","year":"2019","unstructured":"Wang X, He Y, Jiang Y, Feng X, Zhang G, Xia Z, et al. Screening and mutation analysis of hyperphenylalaninemia in newborns from Xiamen. China Clin Chim Acta. 2019;498:161\u20136.","journal-title":"China Clin Chim Acta"},{"issue":"2","key":"1874_CR89","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12519-009-0027-0","volume":"5","author":"JY Zhan","year":"2009","unstructured":"Zhan JY, Qin YF, Zhao ZY. Neonatal screening for congenital hypothyroidism and phenylketonuria in China. World J Pediatr. 2009;5(2):136\u20139.","journal-title":"World J Pediatr"},{"issue":"1\u20132","key":"1874_CR90","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cccn.2004.11.032","volume":"354","author":"HR Yoon","year":"2005","unstructured":"Yoon HR, Lee KR, Kang S, Lee DH, Yoo HW, Min WK, et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin Chim Acta. 2005;354(1\u20132):167\u201380.","journal-title":"Clin Chim Acta"},{"issue":"Suppl 2","key":"1874_CR91","doi-asserted-by":"publisher","first-page":"S295","DOI":"10.1007\/s10545-010-9129-z","volume":"33","author":"DM Niu","year":"2010","unstructured":"Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis. 2010;33(Suppl 2):S295-305.","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T04:00:25Z","timestamp":1725163225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01874-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"17 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RS, KA, and SL are employees of BioMarin Pharmaceutical Inc. PKF was a consultant for BioMarin Pharmaceutical Inc. when this research was conducted. Research team members AH, AVM, BC and MP are full-time employees of RTI Health Solutions. RTI Health Solutions is a unit of RTI International, an independent, nonprofit organization that conducts work for government, public, and private organizations, including pharmaceutical companies. RTI authors participate in this work in the course of employment as work for hire, pursuant to a contract to conduct an independent research study for a client (BioMarin Pharmaceutical Inc.).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}